PACB is up +16.33% intraday to $2.845, extending the prior session's rally from a $2.45 close during regular market hours. The advance follows a wave of catalysts, including the Verily Health multi-year AI collaboration and the EpiSign METRIC 5-base launch on PacBio's HiFi platform.
LUNG is up +38.38% in regular-session trading, rising to $2.74 from its prior close of $1.98. The catalyst is a Q3 2026 earnings beat: EPS of -$0.19 versus -$0.26 expected, and revenue of $22.8M versus $21.93M consensus.
Baird Medical shares declined roughly 66% over the past 30 days, falling from about $0.77 to around $0.26, driven by sustained selling pressure and thin trading liquidity. The move extends a longer downtrend, with the stock down more than 50% over the past three months and roughly 70% over six months.
BDMD is trading down -7.14% to roughly $0.26 during the regular session, extending the prior session's sharp -34% slide. No company-specific announcement drove the move; the decline reflects thin liquidity and profit-taking in a low-priced micro-cap.
BBNX is trading down -12.34% in the regular session, falling to $18.75 from a prior close of $21.39. The selloff follows a securities fraud class action filing tied to iLet device safety issues, which previously triggered a sharp ~37% decline.
Proteus is the pivotal catalyst: The commercial launch of the company's next-generation single-molecule protein sequencing platform has been rescheduled to the second quarter of 2027, making execution against this timeline the dominant driver of the stock forecast. Strategic pivot to non-human proteomics: Management has identified a non-human proteomics opportunity it estimates at more than $4 billion annually, spanning pathogen detection, agriculture, and viral surveillance applications.
The $2.30 central target is the arithmetic mean of three verified analyst price targets reviewed for this article — H.C. Wainwright at $4.00, Alliance Global Partners at $1.90, and Canaccord Genuity at $1.00. With Quantum-Si Incorporated (QSI) recently trading near $1.65, reaching $2.30 would require a gain of roughly 39%, a substantial move.
Quantum-Si (QSI) shares climbed roughly 107% over the last 30 days, rising from $0.795 (Sept. 28 close) to $1.65 (Oct. 27 close). The advance was led by Proteus platform milestones, including demonstrated detection of 19 of 20 amino acids announced on Oct. 8, 2026.
Pulmonx reported third quarter 2026 revenue of $22.8 million , up 6% year over year and above the consensus estimate of $21.93 million. Net loss narrowed 40% to $8.4 million , or $0.19 per share, beating the consensus expectation of a $0.26 per-share loss.
SS Innovations International is expected to report third-quarter 2026 results on or around November 3, 2026, based on its historical reporting schedule. Consensus estimates point to a loss of roughly $0.01 per share on revenue of approximately $14 million, following record second-quarter revenue of $13.9 million.
OrthoPediatrics (KIDS) reported third quarter 2026 revenue of $72.7 million , up 19% from $61.2 million a year earlier, beating consensus estimates. The net loss narrowed to $5.9 million , or $0.25 per share, versus a loss of $11.8 million, or $0.50 per share, in the prior-year quarter.
Beta Bionics reported third quarter 2026 net sales of $35.5 million, up 30% from $27.3 million in the prior-year period. Net loss widened to $24.4 million, or $0.52 per share, from $14.2 million, or $0.33 per share, a year earlier.
GCTK is trading down -18.63% during regular session hours, with shares at $1.31 versus a prior close of $1.61. The pullback follows a +99.65% surge in the prior session, suggesting profit-taking after a sharp speculative run-up.
BDMD dropped -37.21% during regular trading, falling to roughly $0.27 from a prior close of $0.43. The primary pressure is a heavy dilution overhang: an active $50M shelf, an 8% OID convertible note, and registration to resell up to ~45.9M shares.
COCH is trading down -8.15% at $5.97 during regular market hours, following a prior session close of $6.50. The primary driver is post-1-for-10 reverse stock split volatility; the split took effect October 26 to restore Nasdaq's $1 minimum bid compliance, leaving shares gapping and choppy.
The central target of $105 is the average of verified analyst price targets that sit above the current market price, not the headline consensus. The overall mean of all analyst targets is roughly $77, with a wide range from about $50 to $110, reflecting significant disagreement.
10x Genomics (TXG) shares fell roughly 14% over the past 30 days, sliding from about $85.71 to the mid-$73 level and unwinding part of an extended multi-month rally. The decline followed preliminary third-quarter results that missed Wall Street estimates and a cut to full-year revenue guidance, which management attributed to a sales-force reorganization and more cautious customer budgets.
ITOC (iTonic Holdings) is down -12% to $2.42 from the prior close of $2.75, during regular trading hours. The drop extends pressure tied to Nasdaq minimum-bid compliance after an October 6 16-for-1 reverse split, with delisting risk still unresolved.
Perspective Therapeutics shares have fallen roughly 51% over the trailing 30 days, from about $2.52 in late September to near $1.23. The decline accelerated on October 23, when the stock dropped about 29% following interim Phase 1/2a data for its lead program presented at ESMO 2026.
CATX is down -23.6% to about $1.23 during Monday's regular session, extending Friday's -27% slide. Primary catalyst: updated Phase 1/2a VMT-α-NET data at ESMO showed Cohort 2 ORR declining versus prior updates, plus two Grade 3 renal events.